Revance Therapeutics
RVNC
$3.32
Share price
-22.61%
Change (1 day)
-90.56%
Change (1 year)
Categories
Operating Margin for Revance Therapeutics (RVNC)
Operating Margin as of May 2024 (TTM): -212.04%
According to Revance Therapeutics's latest financial reports and stock price the company's current Operating Margin is -212.04%. At the end of 2022 the company had an Operating Margin of -255.91%.
Operating Margin history for Revance Therapeutics from 2013 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2022 | -255.91% | -27.61% |
| 2021 | -353.53% | -79.9% |
| 2020 | -1,758.96% | -95.44% |
| 2019 | -38,602.66% | 931.72% |
| 2018 | -3,741.59% | -91.84% |
| 2017 | -45,851.15% | 55.98% |
| 2016 | -29,396.00% | 22% |
| 2015 | -24,095.33% | 76.64% |
| 2014 | -13,640.99% | 125.74% |
| 2013 | -6,042.79% | 47.87% |
| 2012 | -4,086.47% | -15.92% |
| 2011 | -4,860.50% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 22.88% | -110.79% | 🇺🇸 USA |
 Biogen BIIB | 31.30% | -114.76% | 🇺🇸 USA |
 MediciNova MNOV | -250.93% | 18.34% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.